Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Mostrar outras versões (1)

OBJECTIVES: Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response pr...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Gillies, R, Middleton, MR, Blesing, C, Patel, K, Warner, N, Marshall, R, Maynard, N, Bradley, K, Gleeson, F
Formato:	Journal article
Idioma:	English
Publicado em:	2012

Registros relacionados

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
por: Gillies, R, et al.
Publicado em: (2012)

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
por: Findlay, J, et al.
Publicado em: (2017)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
por: Gillies, R, et al.
Publicado em: (2012)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma
por: Gillies, R, et al.
Publicado em: (2012)

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
por: Findlay, J, et al.
Publicado em: (2017)

Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
por: Gillies, R, et al.
Publicado em: (2011)

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
por: Gillies, R, et al.
Publicado em: (2011)

Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
por: Gillies, R, et al.
Publicado em: (2010)

Predicting pathological response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalised therapy
por: Findlay, J, et al.
Publicado em: (2016)

Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer - a multi-centre retrospective cohort study
por: Teoh, S, et al.
Publicado em: (2016)

The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
por: Chowdhury, F, et al.
Publicado em: (2008)

Neoadjuvant chemotherapy for oesophageal carcinoma - a risk factor for postoperative pneumonia?
por: Millo, J, et al.
Publicado em: (2003)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, J, et al.
Publicado em: (2016)

Survival after curative chemoradiotherapy or neoadjuvant therapy and surgery converges in higher-risk patients with oesophageal cancer
por: Rana, M, et al.
Publicado em: (2021)

Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer
por: den Boer, RB, et al.
Publicado em: (2020)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: John M. Findlay, et al.
Publicado em: (2016-04-01)

A reply to evidence-based radiation oncology: oesophagus.
por: Gillies, R, et al.
Publicado em: (2010)

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
por: Kieran G. Foley, et al.
Publicado em: (2021-06-01)

Adjuvant radiotherapy following neo-adjuvant chemotherapy and surgery in oesophageal cancer: a retrospective cohort study of survival
por: Teoh, S, et al.
Publicado em: (2018)

Assessment of Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and 18F FDG PET/CT
por: Reem Yusuf AlBuainain, et al.
Publicado em: (2025-01-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
por: Tarik Sengoz, et al.
Publicado em: (2023-04-01)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
por: Han Wonshik, et al.
Publicado em: (2011-10-01)

PET/CT staging and response evaluation of post-transplantation lymphoproliferative disease (PTLD).
por: Chowdhury, F, et al.
Publicado em: (2009)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
por: A. G. M. T. Powell, et al.
Publicado em: (2020-08-01)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
por: Alexander M Th Schmitz, et al.
Publicado em: (2017-01-01)

Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis
por: Lihua Chen, et al.
Publicado em: (2017-08-01)

Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery
por: Findlay, J, et al.
Publicado em: (2019)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
por: Turkington, RC, et al.
Publicado em: (2019)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
por: M. K. Ibragimova, et al.
Publicado em: (2022-03-01)

Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer
por: Sun-pyo Hong, et al.
Publicado em: (2024-10-01)

Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
por: Sangwon Han, et al.
Publicado em: (2020-10-01)

Efficacy Of 18FDG-PET/CT In Predicting Response After Neoadjuvant Chemoradiation In Rectal Cancer
por: Narendra Pandit, et al.
Publicado em: (2023-08-01)

Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer
por: Inci Kizildag Yirgin, et al.
Publicado em: (2020-01-01)

The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yao J, et al.
Publicado em: (2021-10-01)

Predictors of complete response to neoadjuvant chemotherapy in non-metastatic bladder cancer
por: P. Sousa Passos, et al.
Publicado em: (2020-11-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy. Additional material
por: M. K. Ibragimova, et al.
Publicado em: (2022-03-01)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
por: Rui-Qin Zhou, et al.
Publicado em: (2023-05-01)

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
por: Giulia Polverari, et al.
Publicado em: (2020-10-01)

Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
por: LU Shengnan, et al.
Publicado em: (2019-02-01)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
por: Willard Wong, et al.
Publicado em: (2021-07-01)